Requested symbol wasn't found

U.S. Markets closed

(CTH.V)


TSXV - TSXV Delayed Price. Currency in USD
Add to watchlist
0.000.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.00
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Marketwired2 years ago

    Cynapsus Therapeutics Announces Proposed Public Offering in the United States, Listing on NASDAQ and Share Consolidation

    Cynapsus Therapeutics Inc. announced today the filing of a registration statement with the US Securities and Exchange Commission relating to a public offering in the United States of its common shares ...

  • Zacks Small Cap Research2 years ago

    CYNAF: Quick Financial Update On Cynapsus

    By Jason Napodano, CFA OTC:CYNAF TSXV:CTH On May 8, 2015, Cynapsus Therapeutics Inc. (OTC:CYNAF) (TSXV:CTH) reported  financial results  for the first quarter ending March 31, 2015. All numbers are in ...

  • Zacks Small Cap Research2 years ago

    Cynapsus Set For Major Revaluation On Positive Phase 2 Data

    On November 19, 2014, Cynapsus Therapeutics Inc. (CYNAF) (CTH.V) announced what looks to be a clear demonstration of proof-of-concept via positive top-line results from the CTH-105 Phase 2 clinical trial. The CTH-105 study was the first to test Cynapsus APL-130277, a fast-acting, sublingual, thin filmstrip formulation of apomorphine in Parkinson’s patient for the management of “off” motor symptoms. The primary objective of CTH-105 (NCT02228590) was to evaluate the efficacy, tolerability and safety of single treatments of APL-130277 in 16 patients with Parkinson's Disease (PD).